EVGN:NASDAQEvogene Ltd. Analysis
Data as of 2026-04-01 - not real-time
$0.80
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Evogene Ltd. (EVGN) is trading at $0.799, barely above the computed support level of $0.72 and well below the 20‑day SMA of $0.814, indicating a fragile price floor. Technicals are bearish – the 20‑day SMA sits under the 50‑day SMA (0.814 vs 0.908) and the 200‑day SMA (1.141), the MACD histogram is negative, and RSI sits at 44.9, suggesting limited upside momentum. Volume is on a decreasing trend and 30‑day volatility is exceptionally high at 78%, flagging a very noisy market environment.
Fundamentally the company is in distress: revenue has collapsed by 80% year‑over‑year to $3.85 M, margins are deeply negative (gross margin –6.3%, operating margin –15.8%), and the latest quarter posted a $5.3 M loss with negative operating and free cash flow. The balance sheet shows a high debt‑to‑equity ratio of 18.4 and a negative book value per share, while the stock carries no dividend. Despite a target price of $1.75 implying >100% upside, the current valuation reflects severe earnings and cash‑flow challenges.
Fundamentally the company is in distress: revenue has collapsed by 80% year‑over‑year to $3.85 M, margins are deeply negative (gross margin –6.3%, operating margin –15.8%), and the latest quarter posted a $5.3 M loss with negative operating and free cash flow. The balance sheet shows a high debt‑to‑equity ratio of 18.4 and a negative book value per share, while the stock carries no dividend. Despite a target price of $1.75 implying >100% upside, the current valuation reflects severe earnings and cash‑flow challenges.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 8/10
Key Factors
- price near technical support with bearish SMA alignment
- recent quarterly loss of $5.3 M and negative cash flow
- decreasing volume and extreme short‑term volatility
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- potential upside to target price if pipeline milestones are met
- still‑negative profitability and high debt burden
- high sector and regulatory uncertainty
Long Term
> 3 yearsPositive
Model confidence: 4/10
Key Factors
- large upside potential relative to current market cap
- computational biology platform could unlock value in agriculture and health
- risk of continued losses may be mitigated by successful product commercialization
Key Metrics & Analysis
Financial Health
Revenue Growth-80.50%
Profit Margin-220.22%
P/E Ratio-1.0
ROE-100.69%
ROA-28.77%
Debt/Equity18.36
P/B Ratio-88.8
Op. Cash Flow$-13502000
Free Cash Flow$-17494624
Industry P/E25.9
Technical Analysis
TrendBearish
RSI44.9
Support$0.72
Resistance$0.97
MA 20$0.81
MA 50$0.91
MA 200$1.14
MACDBearish
VolumeDecreasing
Fear & Greed Index77.34
Valuation
Target Price$1.75
Upside/Downside119.02%
GradeUndervalued
TypeValue
Risk Assessment
Beta0.65
Volatility78.30%
Sector RiskHigh
Reg. RiskHigh
Geo RiskMedium
Currency RiskMedium
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.